Navigating the Complexities of SGLT-2 Inhibitor Therapy: Balancing Benefits and Risks for Type 2 Diabetes Management
Published: 2024-06-19
Page: 75-77
Issue: 2024 - Volume 7 [Issue 1]
Mahadev Khurana *
Chandka Medical College, Larkana, Pakistan.
Sahil Kumar
Chandka Medical College, Larkana, Pakistan.
*Author to whom correspondence should be addressed.
Abstract
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as potent oral hypoglycemic drugs for managing type 2 diabetes, offering significant benefits such as improved cardiovascular and renal functions along with weight loss. However, their usage is accompanied by various risks, including urinary tract infections, vulvovaginal candidiasis, reduced bone mineral density, and the rare but serious condition known as euglycemic diabetic ketoacidosis (EDKA). Despite initial authorizations with perceived benefits outweighing risks, subsequent warnings by the FDA and recent studies have highlighted the elevated risk of diabetic ketoacidosis (DKA) associated with SGLT-2 inhibitors. This risk, particularly EDKA, presents diagnostic challenges due to attenuated hyperglycemia, potentially delaying accurate diagnosis and intervention. Furthermore, the lack of awareness and data in Asian regions underscores the importance of increased vigilance and research into the side effects of these drugs. Clinicians are advised to educate patients about potential adverse effects, consider discontinuation during certain conditions, and utilize advanced glucose meters for the early detection of DKA. This letter emphasizes the critical need for awareness, monitoring, and further investigation into the complexities surrounding SGLT-2 inhibitor therapy in type 2 diabetes management.
Keywords: SGLT-2 inhibitors, type 2 diabetes management, benefits, diabetic ketoacidosis, Euglycemic Diabetic Ketoacidosis (EDKA)
How to Cite
References
Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: Evidence to date. Drug Design, Development and Therapy. 2015:5793-803.
Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, Sreenivasan J, Golzar Y. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta -analysis. European Journal of Preventive Cardiology. 2018;25 (5):495-502.
(FDA), F.a.D.A., FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood; 2015.
(FDA), F.a.D.A., FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the Blood and Serious Urinary Tract Infections; 2015.
Douros A, Lix LM, Fralick M, Dell'Aniello S, Shah BR, Ronksley PE, Tremblay É, Hu N, Alessi-Severini S, Fisher A, Bugden SC. Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study. Annals of Internal Medicine. 2020;173(6):417-25.
Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes/Metabolism Research and Reviews. 2017;33(8):e2924.
IDF Diabetes Atlas; 2021
Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. European Journal of Internal Medicine. 2019;63:9-14.